- Fourth quarter revenue of $772 million; 6% revenue growth; 4% organic growth
- Fourth quarter GAAP EPS of $0.87; Adjusted EPS from continuing operations of $1.70
- Initiates full year 2026 guidance
WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025.
Fourth Quarter 2025
The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same period a year ago. GAAP operating profit margin from continuing operations was 14.5% as a percentage of revenue, as compared to 16.3% in the same period a year ago.
Adjusted earnings per share from continuing operations for the quarter was $1.70, as compared to $1.42 in the same period a year ago. Adjusted operating income was $229 million, as compared to $221 million for the same period a year ago. Adjusted operating profit margin was 29.7% as a percentage of revenue, as compared to 30.3% in the same period a year ago.
Full Year 2025
The Company reported GAAP earnings per share of $2.07 in 2025, as compared to $2.20 in 2024. Revenue for the year was $2,856 million, as compared to $2,755 million in 2024. GAAP operating income from continuing operations for the year was $357 million, as compared to $347 million for 2024. GAAP operating profit margin from continuing operations for the year was 12.5% as a percentage of revenue, as compared to 12.6% in 2024.
Adjusted earnings per share from continuing operations for the year was $5.06, as compared to $4.90 in 2024. Adjusted operating income for the year was $773 million, as compared to $779 million in 2024. Adjusted operating profit margin for the year was 27.1% as a percentage of revenue, as compared to 28.3% in 2024.
Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.
“We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations,” said Prahlad Singh, president and chief executive officer of Revvity. “Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come.”
Financial Overview by Reporting Segment for the Fourth Quarter and Full Year 2025
Life Sciences
- Fourth quarter 2025 revenue was $382 million, as compared to $375 million in the same period a year ago. Revenue increased 2% and organic revenue was flat as compared to the same period a year ago.
- Full year 2025 revenue was $1,431 million, as compared to $1,399 million in 2024. Revenue increased 2% and organic revenue increased 2% as compared to the same period a year ago.
- Fourth quarter 2025 adjusted operating income was $136 million, as compared to $138 million in the same period a year ago. Adjusted operating profit margin was 35.6% as a percentage of revenue, as compared to 36.9% in the same period a year ago.
- Full year 2025 adjusted operating income was $458 million, as compared to $467 million in 2024. Adjusted operating profit margin was 32.0% as a percentage of revenue, as compared to 33.4% in 2024.
Diagnostics
- Fourth quarter 2025 revenue was $390 million, as compared to $355 million in the same period a year ago. Revenue increased 10% and organic revenue increased 7% as compared to the same period a year ago.
- Full year 2025 revenue was $1,425 million, as compared to $1,356 million in 2024. Revenue increased 5% and organic revenue increased 4% as compared to the same period a year ago.
- Fourth quarter 2025 adjusted operating income was $91 million, as compared to $91 million in the same period a year ago. Adjusted operating profit margin was 23.4% as a percentage of revenue, as compared to 25.7% in the same period a year ago.
- Full year 2025 adjusted operating income was $344 million, as compared to $354 million in 2024. Adjusted operating profit margin was 24.2% as a percentage of revenue, as compared to 26.1% in 2024.
Initiates Full Year 2026 Guidance
For the full year 2026, the Company forecasts total revenue of $2.96-$2.99 billion, organic revenue growth of 2-3%, and adjusted earnings per share of $5.35-$5.45.
Guidance for the full year 2026 for organic revenue growth and adjusted EPS is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.
Webcast Information
The Company will discuss its fourth quarter and full year 2025 results and its outlook for business trends during a webcast on February 2, 2026, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website, ir.revvity.com.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes”, “intends”, “anticipates”, “plans”, “expects”, “estimates”, “projects”, “forecasts”, “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
|
Revvity, Inc. and Subsidiaries CONDENSED CONSOLIDATED INCOME STATEMENTS |
||||||||||||||||
|
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||
|
(In thousands, except per share data) |
|
December 28, |
|
December 29, |
|
December 28, |
|
December 29, |
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Revenue |
|
$ |
772,056 |
|
|
$ |
729,372 |
|
|
$ |
2,856,051 |
|
|
$ |
2,755,026 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Cost of revenue |
|
|
350,397 |
|
|
|
317,082 |
|
|
|
1,291,686 |
|
|
|
1,217,367 |
|
|
Selling, general and administrative expenses |
|
|
251,734 |
|
|
|
244,332 |
|
|
|
991,890 |
|
|
|
994,074 |
|
|
Research and development expenses |
|
|
58,176 |
|
|
|
49,208 |
|
|
|
215,840 |
|
|
|
196,844 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Operating income from continuing operations |
|
|
111,749 |
|
|
|
118,750 |
|
|
|
356,635 |
|
|
|
346,741 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Interest income |
|
|
(5,752 |
) |
|
|
(9,828 |
) |
|
|
(31,103 |
) |
|
|
(73,190 |
) |
|
Interest expense |
|
|
23,513 |
|
|
|
22,781 |
|
|
|
92,185 |
|
|
|
96,278 |
|
|
Change in fair value of investments |
|
|
7,972 |
|
|
|
6,017 |
|
|
|
11,456 |
|
|
|
(7,958 |
) |
|
Other (income) expense, net |
|
|
(5,544 |
) |
|
|
5,222 |
|
|
|
15,820 |
|
|
|
15,485 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Income from continuing operations, before income taxes |
|
|
91,560 |
|
|
|
94,558 |
|
|
|
268,277 |
|
|
|
316,126 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
(Benefit from) provision for income taxes |
|
|
(4,211 |
) |
|
|
6,175 |
|
|
|
28,394 |
|
|
|
33,055 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Income from continuing operations |
|
|
95,771 |
|
|
|
88,383 |
|
|
|
239,883 |
|
|
|
283,071 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Income (loss) from discontinued operations |
|
|
2,593 |
|
|
|
6,262 |
|
|
|
1,318 |
|
|
|
(12,686 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net income |
|
$ |
98,364 |
|
|
$ |
94,645 |
|
|
$ |
241,201 |
|
|
$ |
270,385 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Diluted earnings per share: |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Income from continuing operations |
|
$ |
0.85 |
|
|
$ |
0.73 |
|
|
$ |
2.06 |
|
|
$ |
2.30 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Income (loss) from discontinued operations |
|
|
0.02 |
|
|
|
0.05 |
|
|
|
0.01 |
|
|
|
(0.10 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net income |
|
$ |
0.87 |
|
|
$ |
0.78 |
|
|
$ |
2.07 |
|
|
$ |
2.20 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Weighted average diluted shares of common stock outstanding |
|
|
113,214 |
|
|
|
121,581 |
|
|
|
116,595 |
|
|
|
122,822 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
ABOVE PREPARED IN ACCORDANCE WITH GAAP |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Additional supplemental information(1): |
|
|
|
|
|
|
|
|
||||||||
|
(per share, continuing operations) |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
GAAP EPS from continuing operations |
|
$ |
0.85 |
|
|
$ |
0.73 |
|
|
$ |
2.06 |
|
|
$ |
2.30 |
|
|
Amortization of intangible assets |
|
|
0.74 |
|
|
|
0.72 |
|
|
|
2.88 |
|
|
|
2.93 |
|
|
Purchase accounting adjustments |
|
|
(0.01 |
) |
|
|
(0.06 |
) |
|
|
0.01 |
|
|
|
(0.00 |
) |
|
Acquisition and divestiture-related costs |
|
|
0.01 |
|
|
|
0.03 |
|
|
|
0.03 |
|
|
|
0.16 |
|
|
Transformation costs |
|
|
0.03 |
|
|
|
— |
|
|
|
0.08 |
|
|
|
— |
|
|
Change in fair value of investments |
|
|
0.07 |
|
|
|
0.05 |
|
|
|
0.10 |
|
|
|
(0.06 |
) |
|
Asset impairment |
|
|
— |
|
|
|
0.19 |
|
|
|
— |
|
|
|
0.19 |
|
|
Significant litigation matters and settlements |
|
|
— |
|
|
|
0.01 |
|
|
|
0.10 |
|
|
|
0.06 |
|
|
Significant environmental matters |
|
|
— |
|
|
|
— |
|
|
|
(0.01 |
) |
|
|
— |
|
|
Mark to market on postretirement benefits |
|
|
(0.10 |
) |
|
|
0.01 |
|
|
|
(0.05 |
) |
|
|
0.01 |
|
|
Restructuring and other, net |
|
|
0.28 |
|
|
|
(0.04 |
) |
|
|
0.48 |
|
|
|
0.14 |
|
|
Tax on above items |
|
|
(0.19 |
) |
|
|
(0.21 |
) |
|
|
(0.69 |
) |
|
|
(0.83 |
) |
|
Significant tax items |
|
|
0.04 |
|
|
|
— |
|
|
|
0.07 |
|
|
|
— |
|
|
Adjusted EPS from continuing operations |
|
$ |
1.70 |
|
|
$ |
1.42 |
|
|
$ |
5.06 |
|
|
$ |
4.90 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
(1) amounts may not sum due to rounding |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Revvity, Inc. and Subsidiaries REVENUE AND OPERATING INCOME (LOSS) |
||||||||||||||||
|
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||
|
(In thousands, except percentages) |
|
December 28, |
|
December 29, |
|
December 28, |
|
December 29, |
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Revenue and adjusted operating income |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Revenue |
|
$ |
772,056 |
|
|
$ |
729,372 |
|
|
$ |
2,856,051 |
|
|
$ |
2,755,026 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Reported operating income from continuing operations |
|
$ |
111,749 |
|
|
$ |
118,750 |
|
|
$ |
356,635 |
|
|
$ |
346,741 |
|
|
OP% |
|
|
14.5 |
% |
|
|
16.3 |
% |
|
|
12.5 |
% |
|
|
12.6 |
% |
|
Amortization of intangible assets |
|
|
83,523 |
|
|
|
87,876 |
|
|
|
335,586 |
|
|
|
359,376 |
|
|
Purchase accounting adjustments |
|
|
(1,101 |
) |
|
|
(7,427 |
) |
|
|
1,248 |
|
|
|
(79 |
) |
|
Acquisition and divestiture-related costs |
|
|
833 |
|
|
|
3,264 |
|
|
|
3,783 |
|
|
|
25,379 |
|
|
Transformation costs |
|
|
3,054 |
|
|
|
— |
|
|
|
9,280 |
|
|
|
— |
|
|
Asset impairment |
|
|
— |
|
|
|
22,814 |
|
|
|
— |
|
|
|
22,814 |
|
|
Significant litigation matters and settlements |
|
|
(267 |
) |
|
|
689 |
|
|
|
12,228 |
|
|
|
7,775 |
|
|
Significant environmental matters |
|
|
— |
|
|
|
— |
|
|
|
(1,208 |
) |
|
|
— |
|
|
Restructuring and other, net |
|
|
31,564 |
|
|
|
(4,665 |
) |
|
|
55,932 |
|
|
|
17,454 |
|
|
Adjusted operating income |
|
$ |
229,355 |
|
|
$ |
221,301 |
|
|
$ |
773,484 |
|
|
$ |
779,460 |
|
|
OP% |
|
|
29.7 |
% |
|
|
30.3 |
% |
|
|
27.1 |
% |
|
|
28.3 |
% |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Segment revenue and segment operating income |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Life Sciences |
|
$ |
381,989 |
|
|
$ |
374,762 |
|
|
$ |
1,431,104 |
|
|
$ |
1,398,601 |
|
|
Diagnostics |
|
|
390,067 |
|
|
|
354,610 |
|
|
|
1,424,947 |
|
|
|
1,356,425 |
|
|
Segment revenue |
|
|
772,056 |
|
|
|
729,372 |
|
|
|
2,856,051 |
|
|
|
2,755,026 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Life Sciences |
|
$ |
136,034 |
|
|
$ |
138,193 |
|
|
$ |
458,262 |
|
|
$ |
467,276 |
|
|
|
|
|
35.6 |
% |
|
|
36.9 |
% |
|
|
32.0 |
% |
|
|
33.4 |
% |
|
Diagnostics |
|
|
91,353 |
|
|
|
91,137 |
|
|
|
344,166 |
|
|
|
353,938 |
|
|
|
|
|
23.4 |
% |
|
|
25.7 |
% |
|
|
24.2 |
% |
|
|
26.1 |
% |
|
Segment operating income |
|
|
227,387 |
|
|
|
229,330 |
|
|
|
802,428 |
|
|
|
821,214 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Corporate |
|
|
1,968 |
|
|
|
(8,029 |
) |
|
|
(28,944 |
) |
|
|
(41,754 |
) |
|
Adjusted operating income |
|
|
229,355 |
|
|
|
221,301 |
|
|
|
773,484 |
|
|
|
779,460 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Amortization of intangible assets |
|
|
(83,523 |
) |
|
|
(87,876 |
) |
|
|
(335,586 |
) |
|
|
(359,376 |
) |
|
Purchase accounting adjustments |
|
|
1,101 |
|
|
|
7,427 |
|
|
|
(1,248 |
) |
|
|
79 |
|
|
Acquisition and divestiture-related costs |
|
|
(833 |
) |
|
|
(3,264 |
) |
|
|
(3,783 |
) |
|
|
(25,379 |
) |
|
Transformation costs |
|
|
(3,054 |
) |
|
|
— |
|
|
|
(9,280 |
) |
|
|
— |
|
|
Asset impairment |
|
|
— |
|
|
|
(22,814 |
) |
|
|
— |
|
|
|
(22,814 |
) |
|
Significant litigation matters and settlements |
|
|
267 |
|
|
|
(689 |
) |
|
|
(12,228 |
) |
|
|
(7,775 |
) |
|
Significant environmental matters |
|
|
— |
|
|
|
— |
|
|
|
1,208 |
|
|
|
— |
|
|
Restructuring and other, net |
|
|
(31,564 |
) |
|
|
4,665 |
|
|
|
(55,932 |
) |
|
|
(17,454 |
) |
|
Reported operating income from continuing operations |
|
$ |
111,749 |
|
|
$ |
118,750 |
|
|
$ |
356,635 |
|
|
$ |
346,741 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP |
||||||||||||||||
|
Revvity, Inc. and Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||
|
(In thousands) |
December 28, |
|
December 29, |
||
|
|
|
|
|
||
|
Current assets: |
|
|
|
||
|
Cash and cash equivalents |
$ |
919,860 |
|
$ |
1,163,396 |
|
Accounts receivable, net |
|
744,671 |
|
|
632,400 |
|
Inventories, net |
|
379,497 |
|
|
367,587 |
|
Other current assets |
|
195,719 |
|
|
186,225 |
|
Total current assets |
|
2,239,747 |
|
|
2,349,608 |
|
|
|
|
|
||
|
Property, plant and equipment, net |
|
479,249 |
|
|
482,217 |
|
Operating lease right-of-use assets, net |
|
165,439 |
|
|
167,716 |
|
Intangible assets, net |
|
2,347,003 |
|
|
2,640,921 |
|
Goodwill |
|
6,613,493 |
|
|
6,463,619 |
|
Other assets, net |
|
323,480 |
|
|
288,397 |
|
Total assets |
$ |
12,168,411 |
|
$ |
12,392,478 |
|
|
|
|
|
||
|
Current liabilities: |
|
|
|
||
|
Current portion of long-term debt |
$ |
588,828 |
|
$ |
242 |
|
Accounts payable |
|
185,464 |
|
|
167,463 |
|
Accrued expenses and other current liabilities |
|
556,954 |
|
|
485,395 |
|
Total current liabilities |
|
1,331,246 |
|
|
653,100 |
|
|
|
|
|
||
|
Long-term debt |
|
2,631,236 |
|
|
3,150,476 |
|
Long-term liabilities |
|
807,461 |
|
|
770,523 |
|
Operating lease liabilities |
|
148,108 |
|
|
151,505 |
|
Total liabilities |
|
4,918,051 |
|
|
4,725,604 |
|
|
|
|
|
||
|
Total stockholders’ equity |
|
7,250,360 |
|
|
7,666,874 |
|
Total liabilities and stockholders’ equity |
$ |
12,168,411 |
|
$ |
12,392,478 |
|
|
|
|
|
||
|
PREPARED IN ACCORDANCE WITH GAAP |
|||||
|
Revvity, Inc. and Subsidiaries CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||||||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||
|
(In thousands) |
December 28, |
|
December 29, |
|
December 28, |
|
December 29, |
||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
Operating activities: |
|
|
|
|
|
|
|
||||||||
|
Net income |
$ |
98,364 |
|
|
$ |
94,645 |
|
|
$ |
241,201 |
|
|
$ |
270,385 |
|
|
(Income) loss from discontinued operations, net of income taxes |
|
(2,593 |
) |
|
|
(6,262 |
) |
|
|
(1,318 |
) |
|
|
12,686 |
|
|
Income from continuing operations |
|
95,771 |
|
|
|
88,383 |
|
|
|
239,883 |
|
|
|
283,071 |
|
|
Adjustments to reconcile income from continuing operations to net cash provided by continuing operations: |
|
|
|
|
|
|
|
||||||||
|
Stock-based compensation |
|
(4,071 |
) |
|
|
5,053 |
|
|
|
22,847 |
|
|
|
37,809 |
|
|
Restructuring and other, net |
|
31,564 |
|
|
|
(4,665 |
) |
|
|
55,932 |
|
|
|
17,454 |
|
|
Depreciation and amortization |
|
103,079 |
|
|
|
105,033 |
|
|
|
405,340 |
|
|
|
427,849 |
|
|
Pension and other postretirement expenses |
|
3,639 |
|
|
|
9,381 |
|
|
|
3,639 |
|
|
|
9,381 |
|
|
Change in fair value of contingent consideration |
|
(1,341 |
) |
|
|
(7,875 |
) |
|
|
(1,400 |
) |
|
|
(1,869 |
) |
|
Deferred taxes |
|
(61,483 |
) |
|
|
(102,232 |
) |
|
|
(61,483 |
) |
|
|
(102,232 |
) |
|
Contingencies and non-cash tax matters |
|
(86 |
) |
|
|
(8,073 |
) |
|
|
(86 |
) |
|
|
(8,073 |
) |
|
Amortization of deferred debt financing costs and accretion of discounts |
|
992 |
|
|
|
1,022 |
|
|
|
4,552 |
|
|
|
6,073 |
|
|
Change in fair value of investments |
|
7,972 |
|
|
|
6,017 |
|
|
|
11,456 |
|
|
|
(7,958 |
) |
|
Unrealized foreign exchange loss (gain) |
|
51 |
|
|
|
4 |
|
|
|
273 |
|
|
|
(1,059 |
) |
|
Asset impairment |
|
4,784 |
|
|
|
22,814 |
|
|
|
4,784 |
|
|
|
22,814 |
|
|
Changes in assets and liabilities which provided (used) cash: |
|
|
|
|
|
|
|
||||||||
|
Accounts receivable, net |
|
(59,380 |
) |
|
|
(49,260 |
) |
|
|
(101,023 |
) |
|
|
(15,969 |
) |
|
Inventories, net |
|
2,289 |
|
|
|
18,269 |
|
|
|
14,782 |
|
|
|
45,086 |
|
|
Accounts payable |
|
7,075 |
|
|
|
(1,243 |
) |
|
|
7,345 |
|
|
|
(26,025 |
) |
|
Accrued expenses and other |
|
51,105 |
|
|
|
92,839 |
|
|
|
(17,885 |
) |
|
|
(21,397 |
) |
|
Net cash provided by operating activities of continuing operations |
|
181,960 |
|
|
|
175,467 |
|
|
|
588,956 |
|
|
|
664,955 |
|
|
Net cash used in operating activities of discontinued operations |
|
— |
|
|
|
(1,237 |
) |
|
|
(6,023 |
) |
|
|
(36,656 |
) |
|
Net cash provided by operating activities |
|
181,960 |
|
|
|
174,230 |
|
|
|
582,933 |
|
|
|
628,299 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Investing activities: |
|
|
|
|
|
|
|
||||||||
|
Capital expenditures |
|
(20,171 |
) |
|
|
(24,454 |
) |
|
|
(73,522 |
) |
|
|
(86,648 |
) |
|
Purchases of investments and notes receivables |
|
(356 |
) |
|
|
(2,250 |
) |
|
|
(385 |
) |
|
|
(6,587 |
) |
|
Proceeds from investments and notes receivables |
|
75 |
|
|
|
— |
|
|
|
75 |
|
|
|
2,500 |
|
|
Proceeds from U.S. Treasury Securities |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
710,000 |
|
|
Proceeds from disposition of businesses and assets |
|
— |
|
|
|
— |
|
|
|
229 |
|
|
|
— |
|
|
Net cash (used in) provided by investing activities of continuing operations |
|
(20,452 |
) |
|
|
(26,704 |
) |
|
|
(73,603 |
) |
|
|
619,265 |
|
|
Net cash provided by investing activities of discontinued operations |
|
— |
|
|
|
9,375 |
|
|
|
56,250 |
|
|
|
156,897 |
|
|
Net cash (used in) provided by investing activities |
|
(20,452 |
) |
|
|
(17,329 |
) |
|
|
(17,353 |
) |
|
|
776,162 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Financing Activities: |
|
|
|
|
|
|
|
||||||||
|
Payments of debt financing costs |
|
— |
|
|
|
— |
|
|
|
(2,474 |
) |
|
|
— |
|
|
Payments of senior unsecured notes |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(711,479 |
) |
|
Payments on other credit facilities |
|
(363 |
) |
|
|
(822 |
) |
|
|
(521 |
) |
|
|
(11,593 |
) |
|
Payments for acquisition-related contingent consideration |
|
— |
|
|
|
— |
|
|
|
(3,838 |
) |
|
|
(8,832 |
) |
|
Proceeds from issuance of common stock under stock plans |
|
293 |
|
|
|
1,528 |
|
|
|
2,925 |
|
|
|
7,701 |
|
|
Purchases of common stock |
|
(168,285 |
) |
|
|
(185,157 |
) |
|
|
(820,815 |
) |
|
|
(369,578 |
) |
|
Dividends paid |
|
(7,955 |
) |
|
|
(8,539 |
) |
|
|
(32,800 |
) |
|
|
(34,454 |
) |
|
Net cash used in financing activities of continuing operations |
|
(176,310 |
) |
|
|
(192,990 |
) |
|
|
(857,523 |
) |
|
|
(1,128,235 |
) |
|
|
|
|
|
|
|
|
|
||||||||
|
Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
|
3,257 |
|
|
|
(30,267 |
) |
|
|
48,521 |
|
|
|
(26,147 |
) |
|
|
|
|
|
|
|
|
|
||||||||
|
Net (decrease) increase in cash, cash equivalents, and restricted cash |
|
(11,545 |
) |
|
|
(66,356 |
) |
|
|
(243,422 |
) |
|
|
250,079 |
|
|
Cash, cash equivalents, and restricted cash at beginning of period |
|
932,575 |
|
|
|
1,230,808 |
|
|
|
1,164,452 |
|
|
|
914,373 |
|
|
Cash, cash equivalents, and restricted cash at end of period |
$ |
921,030 |
|
|
$ |
1,164,452 |
|
|
$ |
921,030 |
|
|
$ |
1,164,452 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
|
||||||||
|
Reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total shown in the consolidated statements of cash flows: |
|
|
|
|
|
|
|
||||||||
|
Cash and cash equivalents |
$ |
919,860 |
|
|
$ |
1,163,396 |
|
|
$ |
919,860 |
|
|
$ |
1,163,396 |
|
|
Restricted cash included in other current assets |
|
6 |
|
|
|
1,056 |
|
|
|
6 |
|
|
|
1,056 |
|
|
Restricted cash included in other assets |
|
1,164 |
|
|
|
— |
|
|
|
1,164 |
|
|
|
— |
|
|
Total cash, cash equivalents and restricted cash |
$ |
921,030 |
|
|
$ |
1,164,452 |
|
|
$ |
921,030 |
|
|
$ |
1,164,452 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
PREPARED IN ACCORDANCE WITH GAAP |
|||||||||||||||
|
Revvity, Inc. and Subsidiaries RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1) |
|||
|
|
|
|
Continuing Operations |
|
|
|
|
Three Months Ended |
|
|
|
|
December 28, 2025 |
|
Organic revenue growth: |
|
|
|
|
Revenue growth from continuing operations |
|
|
6% |
|
Less: effect of foreign exchange rates |
|
|
2% |
|
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses |
|
|
0% |
|
Organic revenue growth from continuing operations |
|
|
4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Life Sciences |
|
|
|
|
Three Months Ended |
|
|
|
|
December 28, 2025 |
|
Organic revenue growth: |
|
|
|
|
Revenue growth from continuing operations |
|
|
2% |
|
Less: effect of foreign exchange rates |
|
|
2% |
|
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses |
|
|
0% |
|
Organic revenue growth from continuing operations |
|
|
0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics |
|
|
|
|
Three Months Ended |
|
|
|
|
December 28, 2025 |
|
Organic revenue growth: |
|
|
|
|
Revenue growth from continuing operations |
|
|
10% |
|
Less: effect of foreign exchange rates |
|
|
3% |
|
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses |
|
|
0% |
|
Organic revenue growth from continuing operations |
|
|
7% |
|
|
|
|
|
|
|
|
|
|
|
(1) amounts may not sum due to rounding |
|
|
|
|
Revvity, Inc. and Subsidiaries RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1) |
|||
|
|
|
|
Continuing Operations |
|
|
|
|
Twelve Months Ended |
|
|
|
|
December 28, 2025 |
|
Organic revenue growth: |
|
|
|
|
Revenue growth from continuing operations |
|
|
4% |
|
Less: effect of foreign exchange rates |
|
|
1% |
|
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses |
|
|
0% |
|
Organic revenue growth from continuing operations |
|
|
3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Life Sciences |
|
|
|
|
Twelve Months Ended |
|
|
|
|
December 28, 2025 |
|
Organic revenue growth: |
|
|
|
|
Revenue growth from continuing operations |
|
|
2% |
|
Less: effect of foreign exchange rates |
|
|
1% |
|
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses |
|
|
0% |
|
Organic revenue growth from continuing operations |
|
|
2% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics |
|
|
|
|
Twelve Months Ended |
|
|
|
|
December 28, 2025 |
|
Organic revenue growth: |
|
|
|
|
Revenue growth from continuing operations |
|
|
5% |
|
Less: effect of foreign exchange rates |
|
|
1% |
|
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses |
|
|
0% |
|
Organic revenue growth from continuing operations |
|
|
4% |
|
|
|
|
|
|
(1) amounts may not sum due to rounding |
|
|
|
|
Revvity, Inc. and Subsidiaries FY 2026 ORGANIC REVENUE GROWTH FORECAST (1) |
|||
|
|
|
|
Continuing Operations |
|
|
|
|
Twelve Months Ended |
|
|
|
|
January 3, 2027 |
|
|
|
|
Projected |
|
Organic revenue growth: |
|
|
|
|
Revenue growth from continuing operations |
|
|
4% – 5% |
|
Less: effect of foreign exchange rates |
|
|
1% |
|
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses |
|
|
1% |
|
Organic revenue growth from continuing operations |
|
|
2% – 3% |
|
|
|
|
|
|
(1) amounts may not sum due to rounding |
|
|
|
Contacts
Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com
Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com